Outset Medical, Inc.
Outset Medical, Inc. (OM) Stock Competitors & Peer Comparison
See (OM) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| OM | $3.70 | -20.94% | 68.5M | -0.69 | -$5.37 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $84.32 | -3.09% | 146.8B | 23.61 | $3.57 | +2.89% |
| SYK | $285.47 | -2.98% | 109.4B | 34.03 | $8.39 | +1.20% |
| MDT | $76.15 | -2.32% | 97.8B | 21.27 | $3.58 | +3.73% |
| BSX | $53.93 | -4.68% | 80.2B | 22.57 | $2.39 | N/A |
| BRKRP | $342.89 | +1.56% | 52B | N/A | N/A | +0.46% |
| EW | $79.96 | -3.38% | 46B | 43.21 | $1.85 | N/A |
| PHG | $27.21 | +0.18% | 25.9B | 23.26 | $1.17 | +3.56% |
| DXCM | $60.61 | -0.49% | 23.4B | 26.01 | $2.33 | N/A |
Stock Comparison
OM vs BSX-PA Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, OM is priced at $3.70, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, OM's ROE is -0.56%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, OM is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check BSX-PA's competition here
OM vs ABT Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, ABT has a market cap of 146.8B. Regarding current trading prices, OM is priced at $3.70, while ABT trades at $84.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas ABT's P/E ratio is 23.61. In terms of profitability, OM's ROE is -0.56%, compared to ABT's ROE of +0.12%. Regarding short-term risk, OM is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check ABT's competition here
OM vs SYK Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, SYK has a market cap of 109.4B. Regarding current trading prices, OM is priced at $3.70, while SYK trades at $285.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas SYK's P/E ratio is 34.03. In terms of profitability, OM's ROE is -0.56%, compared to SYK's ROE of +0.15%. Regarding short-term risk, OM is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check SYK's competition here
OM vs MDT Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, MDT has a market cap of 97.8B. Regarding current trading prices, OM is priced at $3.70, while MDT trades at $76.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas MDT's P/E ratio is 21.27. In terms of profitability, OM's ROE is -0.56%, compared to MDT's ROE of +0.10%. Regarding short-term risk, OM is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check MDT's competition here
OM vs BSX Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, BSX has a market cap of 80.2B. Regarding current trading prices, OM is priced at $3.70, while BSX trades at $53.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas BSX's P/E ratio is 22.57. In terms of profitability, OM's ROE is -0.56%, compared to BSX's ROE of +0.15%. Regarding short-term risk, OM is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check BSX's competition here
OM vs BRKRP Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, BRKRP has a market cap of 52B. Regarding current trading prices, OM is priced at $3.70, while BRKRP trades at $342.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas BRKRP's P/E ratio is N/A. In terms of profitability, OM's ROE is -0.56%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, OM is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check BRKRP's competition here
OM vs EW Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, EW has a market cap of 46B. Regarding current trading prices, OM is priced at $3.70, while EW trades at $79.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas EW's P/E ratio is 43.21. In terms of profitability, OM's ROE is -0.56%, compared to EW's ROE of +0.11%. Regarding short-term risk, OM is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check EW's competition here
OM vs PHG Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, PHG has a market cap of 25.9B. Regarding current trading prices, OM is priced at $3.70, while PHG trades at $27.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas PHG's P/E ratio is 23.26. In terms of profitability, OM's ROE is -0.56%, compared to PHG's ROE of +0.09%. Regarding short-term risk, OM is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check PHG's competition here
OM vs DXCM Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, DXCM has a market cap of 23.4B. Regarding current trading prices, OM is priced at $3.70, while DXCM trades at $60.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas DXCM's P/E ratio is 26.01. In terms of profitability, OM's ROE is -0.56%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, OM is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check DXCM's competition here
OM vs STE Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, STE has a market cap of 20.4B. Regarding current trading prices, OM is priced at $3.70, while STE trades at $207.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas STE's P/E ratio is 29.26. In terms of profitability, OM's ROE is -0.56%, compared to STE's ROE of +0.10%. Regarding short-term risk, OM is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check STE's competition here
OM vs ABMD Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, OM is priced at $3.70, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas ABMD's P/E ratio is 65.36. In terms of profitability, OM's ROE is -0.56%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, OM is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check ABMD's competition here
OM vs ZBH Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, ZBH has a market cap of 15.9B. Regarding current trading prices, OM is priced at $3.70, while ZBH trades at $82.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas ZBH's P/E ratio is 21.38. In terms of profitability, OM's ROE is -0.56%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, OM is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check ZBH's competition here
OM vs SNN Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, SNN has a market cap of 12.8B. Regarding current trading prices, OM is priced at $3.70, while SNN trades at $29.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas SNN's P/E ratio is 20.95. In terms of profitability, OM's ROE is -0.56%, compared to SNN's ROE of +0.12%. Regarding short-term risk, OM is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check SNN's competition here
OM vs PEN Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, OM is priced at $3.70, while PEN trades at $322.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas PEN's P/E ratio is 74.08. In terms of profitability, OM's ROE is -0.56%, compared to PEN's ROE of +0.12%. Regarding short-term risk, OM is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check PEN's competition here
OM vs SWAV Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, OM is priced at $3.70, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas SWAV's P/E ratio is 78.76. In terms of profitability, OM's ROE is -0.56%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, OM is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check SWAV's competition here
OM vs ALGN Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, ALGN has a market cap of 12.1B. Regarding current trading prices, OM is priced at $3.70, while ALGN trades at $168.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas ALGN's P/E ratio is 28.32. In terms of profitability, OM's ROE is -0.56%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, OM is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check ALGN's competition here
OM vs PODD Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, PODD has a market cap of 10.7B. Regarding current trading prices, OM is priced at $3.70, while PODD trades at $154.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas PODD's P/E ratio is 36.02. In terms of profitability, OM's ROE is -0.56%, compared to PODD's ROE of +0.21%. Regarding short-term risk, OM is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check PODD's competition here
OM vs GMED Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, GMED has a market cap of 10.5B. Regarding current trading prices, OM is priced at $3.70, while GMED trades at $77.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas GMED's P/E ratio is 18.21. In terms of profitability, OM's ROE is -0.56%, compared to GMED's ROE of +0.13%. Regarding short-term risk, OM is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check GMED's competition here
OM vs GKOS Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, GKOS has a market cap of 7.8B. Regarding current trading prices, OM is priced at $3.70, while GKOS trades at $133.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas GKOS's P/E ratio is -40.44. In terms of profitability, OM's ROE is -0.56%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, OM is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check GKOS's competition here
OM vs BIO-B Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, BIO-B has a market cap of 6.9B. Regarding current trading prices, OM is priced at $3.70, while BIO-B trades at $255.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas BIO-B's P/E ratio is 42.52. In terms of profitability, OM's ROE is -0.56%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, OM is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check BIO-B's competition here
OM vs BIO Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, BIO has a market cap of 6.9B. Regarding current trading prices, OM is priced at $3.70, while BIO trades at $254.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas BIO's P/E ratio is 42.32. In terms of profitability, OM's ROE is -0.56%, compared to BIO's ROE of +0.02%. Regarding short-term risk, OM is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check BIO's competition here
OM vs BRKR Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, BRKR has a market cap of 6.7B. Regarding current trading prices, OM is priced at $3.70, while BRKR trades at $44.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas BRKR's P/E ratio is -184.00. In terms of profitability, OM's ROE is -0.56%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, OM is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check BRKR's competition here
OM vs NARI Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, OM is priced at $3.70, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas NARI's P/E ratio is -59.24. In terms of profitability, OM's ROE is -0.56%, compared to NARI's ROE of -0.00%. Regarding short-term risk, OM is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check NARI's competition here
OM vs IRTC Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, IRTC has a market cap of 4B. Regarding current trading prices, OM is priced at $3.70, while IRTC trades at $120.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas IRTC's P/E ratio is -141.95. In terms of profitability, OM's ROE is -0.56%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, OM is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check IRTC's competition here
OM vs LIVN Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, LIVN has a market cap of 3.9B. Regarding current trading prices, OM is priced at $3.70, while LIVN trades at $71.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas LIVN's P/E ratio is 36.66. In terms of profitability, OM's ROE is -0.56%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, OM is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check LIVN's competition here
OM vs AXNX Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, OM is priced at $3.70, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas AXNX's P/E ratio is -709.80. In terms of profitability, OM's ROE is -0.56%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, OM is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check AXNX's competition here
OM vs ITGR Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, OM is priced at $3.70, while ITGR trades at $88.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas ITGR's P/E ratio is 21.86. In terms of profitability, OM's ROE is -0.56%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, OM is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check ITGR's competition here
OM vs TMDX Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, TMDX has a market cap of 2.3B. Regarding current trading prices, OM is priced at $3.70, while TMDX trades at $67.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas TMDX's P/E ratio is 15.51. In terms of profitability, OM's ROE is -0.56%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, OM is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check TMDX's competition here
OM vs AXGN Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, OM is priced at $3.70, while AXGN trades at $42.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas AXGN's P/E ratio is -66.76. In terms of profitability, OM's ROE is -0.56%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, OM is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check AXGN's competition here
OM vs ESTA Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, OM is priced at $3.70, while ESTA trades at $71.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas ESTA's P/E ratio is -48.82. In terms of profitability, OM's ROE is -0.56%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, OM is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check ESTA's competition here
OM vs NUVA Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, OM is priced at $3.70, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas NUVA's P/E ratio is 75.00. In terms of profitability, OM's ROE is -0.56%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, OM is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check NUVA's competition here
OM vs UFPT Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, OM is priced at $3.70, while UFPT trades at $230.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas UFPT's P/E ratio is 26.29. In terms of profitability, OM's ROE is -0.56%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, OM is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check UFPT's competition here
OM vs AHCO Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, AHCO has a market cap of 1.5B. Regarding current trading prices, OM is priced at $3.70, while AHCO trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas AHCO's P/E ratio is -19.15. In terms of profitability, OM's ROE is -0.56%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, OM is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check AHCO's competition here
OM vs PRCT Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, PRCT has a market cap of 1.4B. Regarding current trading prices, OM is priced at $3.70, while PRCT trades at $25.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas PRCT's P/E ratio is -13.88. In terms of profitability, OM's ROE is -0.56%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, OM is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check PRCT's competition here
OM vs HSKA Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, OM is priced at $3.70, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas HSKA's P/E ratio is -62.49. In terms of profitability, OM's ROE is -0.56%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, OM is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check HSKA's competition here
OM vs INSP Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, INSP has a market cap of 1.3B. Regarding current trading prices, OM is priced at $3.70, while INSP trades at $44.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas INSP's P/E ratio is 10.05. In terms of profitability, OM's ROE is -0.56%, compared to INSP's ROE of +0.18%. Regarding short-term risk, OM is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check INSP's competition here
OM vs AORT Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, OM is priced at $3.70, while AORT trades at $25.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas AORT's P/E ratio is 120.95. In terms of profitability, OM's ROE is -0.56%, compared to AORT's ROE of +0.03%. Regarding short-term risk, OM is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for OM.Check AORT's competition here
OM vs AVNS Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, OM is priced at $3.70, while AVNS trades at $24.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas AVNS's P/E ratio is -15.50. In terms of profitability, OM's ROE is -0.56%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, OM is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check AVNS's competition here
OM vs ATEC Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, OM is priced at $3.70, while ATEC trades at $7.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas ATEC's P/E ratio is -9.06. In terms of profitability, OM's ROE is -0.56%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, OM is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check ATEC's competition here
OM vs SILK Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, OM is priced at $3.70, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas SILK's P/E ratio is -18.96. In terms of profitability, OM's ROE is -0.56%, compared to SILK's ROE of -0.35%. Regarding short-term risk, OM is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check SILK's competition here
OM vs CNMD Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, OM is priced at $3.70, while CNMD trades at $36.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas CNMD's P/E ratio is 20.77. In terms of profitability, OM's ROE is -0.56%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, OM is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check CNMD's competition here
OM vs IRMD Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, OM is priced at $3.70, while IRMD trades at $86.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas IRMD's P/E ratio is 47.15. In terms of profitability, OM's ROE is -0.56%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, OM is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check IRMD's competition here
OM vs FNA Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, OM is priced at $3.70, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas FNA's P/E ratio is -19.83. In terms of profitability, OM's ROE is -0.56%, compared to FNA's ROE of -0.35%. Regarding short-term risk, OM is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check FNA's competition here
OM vs BFLY Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, BFLY has a market cap of 1.1B. Regarding current trading prices, OM is priced at $3.70, while BFLY trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas BFLY's P/E ratio is -13.88. In terms of profitability, OM's ROE is -0.56%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, OM is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check BFLY's competition here
OM vs IART Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, OM is priced at $3.70, while IART trades at $13.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas IART's P/E ratio is -2.15. In terms of profitability, OM's ROE is -0.56%, compared to IART's ROE of -0.48%. Regarding short-term risk, OM is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check IART's competition here
OM vs TNDM Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, OM is priced at $3.70, while TNDM trades at $15.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas TNDM's P/E ratio is -5.09. In terms of profitability, OM's ROE is -0.56%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, OM is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for OM.Check TNDM's competition here
OM vs LMRI Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, LMRI has a market cap of 1B. Regarding current trading prices, OM is priced at $3.70, while LMRI trades at $10.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas LMRI's P/E ratio is -15.79. In terms of profitability, OM's ROE is -0.56%, compared to LMRI's ROE of -0.18%. Regarding short-term risk, OM is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check LMRI's competition here
OM vs INMD Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, INMD has a market cap of 884.5M. Regarding current trading prices, OM is priced at $3.70, while INMD trades at $13.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas INMD's P/E ratio is 10.34. In terms of profitability, OM's ROE is -0.56%, compared to INMD's ROE of +0.13%. Regarding short-term risk, OM is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check INMD's competition here
OM vs CSII Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, OM is priced at $3.70, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas CSII's P/E ratio is -20.83. In terms of profitability, OM's ROE is -0.56%, compared to CSII's ROE of -0.14%. Regarding short-term risk, OM is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check CSII's competition here
OM vs SSII Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, SSII has a market cap of 774.5M. Regarding current trading prices, OM is priced at $3.70, while SSII trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas SSII's P/E ratio is -64.50. In terms of profitability, OM's ROE is -0.56%, compared to SSII's ROE of -0.30%. Regarding short-term risk, OM is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check SSII's competition here
OM vs CBLL Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, CBLL has a market cap of 765M. Regarding current trading prices, OM is priced at $3.70, while CBLL trades at $20.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas CBLL's P/E ratio is -13.84. In terms of profitability, OM's ROE is -0.56%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, OM is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check CBLL's competition here
OM vs CRY Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, OM is priced at $3.70, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas CRY's P/E ratio is 425.71. In terms of profitability, OM's ROE is -0.56%, compared to CRY's ROE of +0.03%. Regarding short-term risk, OM is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check CRY's competition here
OM vs BVS Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, BVS has a market cap of 710.2M. Regarding current trading prices, OM is priced at $3.70, while BVS trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas BVS's P/E ratio is 25.61. In terms of profitability, OM's ROE is -0.56%, compared to BVS's ROE of +0.16%. Regarding short-term risk, OM is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check BVS's competition here
OM vs BWAY Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, BWAY has a market cap of 673.5M. Regarding current trading prices, OM is priced at $3.70, while BWAY trades at $17.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas BWAY's P/E ratio is 95.39. In terms of profitability, OM's ROE is -0.56%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, OM is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check BWAY's competition here
OM vs NPCE Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, NPCE has a market cap of 622.7M. Regarding current trading prices, OM is priced at $3.70, while NPCE trades at $18.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas NPCE's P/E ratio is -27.79. In terms of profitability, OM's ROE is -0.56%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, OM is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check NPCE's competition here
OM vs SRDX Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, OM is priced at $3.70, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas SRDX's P/E ratio is -34.66. In terms of profitability, OM's ROE is -0.56%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, OM is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check SRDX's competition here
OM vs CTKB Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, CTKB has a market cap of 592.6M. Regarding current trading prices, OM is priced at $3.70, while CTKB trades at $4.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas CTKB's P/E ratio is -8.87. In terms of profitability, OM's ROE is -0.56%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, OM is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check CTKB's competition here
OM vs APEN Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, OM is priced at $3.70, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas APEN's P/E ratio is -9.43. In terms of profitability, OM's ROE is -0.56%, compared to APEN's ROE of -0.85%. Regarding short-term risk, OM is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check APEN's competition here
OM vs TCMD Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, TCMD has a market cap of 578.6M. Regarding current trading prices, OM is priced at $3.70, while TCMD trades at $25.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas TCMD's P/E ratio is 29.48. In terms of profitability, OM's ROE is -0.56%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, OM is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check TCMD's competition here
OM vs SIBN Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, SIBN has a market cap of 542.9M. Regarding current trading prices, OM is priced at $3.70, while SIBN trades at $12.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas SIBN's P/E ratio is -27.89. In terms of profitability, OM's ROE is -0.56%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, OM is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check SIBN's competition here
OM vs ZIMV Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, OM is priced at $3.70, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, OM's ROE is -0.56%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, OM is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check ZIMV's competition here
OM vs CERS Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, CERS has a market cap of 523M. Regarding current trading prices, OM is priced at $3.70, while CERS trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas CERS's P/E ratio is -52.20. In terms of profitability, OM's ROE is -0.56%, compared to CERS's ROE of -0.15%. Regarding short-term risk, OM is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check CERS's competition here
OM vs OFIX Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, OFIX has a market cap of 470.9M. Regarding current trading prices, OM is priced at $3.70, while OFIX trades at $11.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas OFIX's P/E ratio is -7.77. In terms of profitability, OM's ROE is -0.56%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, OM is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check OFIX's competition here
OM vs KIDS Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, KIDS has a market cap of 457.4M. Regarding current trading prices, OM is priced at $3.70, while KIDS trades at $17.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas KIDS's P/E ratio is -10.60. In terms of profitability, OM's ROE is -0.56%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, OM is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check KIDS's competition here
OM vs PACB Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, PACB has a market cap of 425.8M. Regarding current trading prices, OM is priced at $3.70, while PACB trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas PACB's P/E ratio is -0.77. In terms of profitability, OM's ROE is -0.56%, compared to PACB's ROE of -2.48%. Regarding short-term risk, OM is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check PACB's competition here
OM vs VREX Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, VREX has a market cap of 412.1M. Regarding current trading prices, OM is priced at $3.70, while VREX trades at $9.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas VREX's P/E ratio is -5.99. In terms of profitability, OM's ROE is -0.56%, compared to VREX's ROE of -0.18%. Regarding short-term risk, OM is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for OM.Check VREX's competition here
OM vs DCTH Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, DCTH has a market cap of 398.9M. Regarding current trading prices, OM is priced at $3.70, while DCTH trades at $11.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas DCTH's P/E ratio is 164.00. In terms of profitability, OM's ROE is -0.56%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, OM is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check DCTH's competition here
OM vs LAB Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, LAB has a market cap of 398.2M. Regarding current trading prices, OM is priced at $3.70, while LAB trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas LAB's P/E ratio is -8.50. In terms of profitability, OM's ROE is -0.56%, compared to LAB's ROE of +0.17%. Regarding short-term risk, OM is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check LAB's competition here
OM vs CLPT Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, CLPT has a market cap of 384.4M. Regarding current trading prices, OM is priced at $3.70, while CLPT trades at $12.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas CLPT's P/E ratio is -14.57. In terms of profitability, OM's ROE is -0.56%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, OM is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check CLPT's competition here
OM vs VMD Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, VMD has a market cap of 342.7M. Regarding current trading prices, OM is priced at $3.70, while VMD trades at $8.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas VMD's P/E ratio is 24.16. In terms of profitability, OM's ROE is -0.56%, compared to VMD's ROE of +0.11%. Regarding short-term risk, OM is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check VMD's competition here
OM vs PMI Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, PMI has a market cap of 327.9M. Regarding current trading prices, OM is priced at $3.70, while PMI trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas PMI's P/E ratio is -0.28. In terms of profitability, OM's ROE is -0.56%, compared to PMI's ROE of +2.17%. Regarding short-term risk, OM is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for OM.Check PMI's competition here
OM vs SMLR Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, OM is priced at $3.70, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas SMLR's P/E ratio is 3.92. In terms of profitability, OM's ROE is -0.56%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, OM is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check SMLR's competition here
OM vs MASS Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, MASS has a market cap of 308.9M. Regarding current trading prices, OM is priced at $3.70, while MASS trades at $8.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas MASS's P/E ratio is -8.42. In terms of profitability, OM's ROE is -0.56%, compared to MASS's ROE of -0.26%. Regarding short-term risk, OM is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check MASS's competition here
OM vs SGHT Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, SGHT has a market cap of 292.7M. Regarding current trading prices, OM is priced at $3.70, while SGHT trades at $5.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas SGHT's P/E ratio is -7.69. In terms of profitability, OM's ROE is -0.56%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, OM is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check SGHT's competition here
OM vs CATX Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, CATX has a market cap of 277.7M. Regarding current trading prices, OM is priced at $3.70, while CATX trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas CATX's P/E ratio is -2.67. In terms of profitability, OM's ROE is -0.56%, compared to CATX's ROE of -0.41%. Regarding short-term risk, OM is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check CATX's competition here
OM vs MGRM Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, OM is priced at $3.70, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas MGRM's P/E ratio is -11.11. In terms of profitability, OM's ROE is -0.56%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, OM is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check MGRM's competition here
OM vs RXST Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, RXST has a market cap of 242.2M. Regarding current trading prices, OM is priced at $3.70, while RXST trades at $5.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas RXST's P/E ratio is -6.16. In terms of profitability, OM's ROE is -0.56%, compared to RXST's ROE of -0.17%. Regarding short-term risk, OM is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check RXST's competition here
OM vs AVR Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, AVR has a market cap of 242.1M. Regarding current trading prices, OM is priced at $3.70, while AVR trades at $6.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas AVR's P/E ratio is -2.58. In terms of profitability, OM's ROE is -0.56%, compared to AVR's ROE of -5.28%. Regarding short-term risk, OM is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check AVR's competition here
OM vs NVRO Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, OM is priced at $3.70, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas NVRO's P/E ratio is -1.91. In terms of profitability, OM's ROE is -0.56%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, OM is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check NVRO's competition here
OM vs ELMD Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, ELMD has a market cap of 222.9M. Regarding current trading prices, OM is priced at $3.70, while ELMD trades at $26.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas ELMD's P/E ratio is 26.15. In terms of profitability, OM's ROE is -0.56%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, OM is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check ELMD's competition here
OM vs SENS Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, SENS has a market cap of 210.1M. Regarding current trading prices, OM is priced at $3.70, while SENS trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas SENS's P/E ratio is -3.03. In terms of profitability, OM's ROE is -0.56%, compared to SENS's ROE of -1.31%. Regarding short-term risk, OM is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for OM.Check SENS's competition here
OM vs EYES Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, OM is priced at $3.70, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas EYES's P/E ratio is N/A. In terms of profitability, OM's ROE is -0.56%, compared to EYES's ROE of -3.17%. Regarding short-term risk, OM is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check EYES's competition here
OM vs PROF Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, PROF has a market cap of 207.3M. Regarding current trading prices, OM is priced at $3.70, while PROF trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas PROF's P/E ratio is -4.86. In terms of profitability, OM's ROE is -0.56%, compared to PROF's ROE of -0.45%. Regarding short-term risk, OM is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check PROF's competition here
OM vs ANIK Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, ANIK has a market cap of 196.5M. Regarding current trading prices, OM is priced at $3.70, while ANIK trades at $14.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas ANIK's P/E ratio is -18.70. In terms of profitability, OM's ROE is -0.56%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, OM is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check ANIK's competition here
OM vs INGN Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, INGN has a market cap of 191.8M. Regarding current trading prices, OM is priced at $3.70, while INGN trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas INGN's P/E ratio is -8.16. In terms of profitability, OM's ROE is -0.56%, compared to INGN's ROE of -0.13%. Regarding short-term risk, OM is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check INGN's competition here
OM vs BSGM Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, OM is priced at $3.70, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas BSGM's P/E ratio is -5.81. In terms of profitability, OM's ROE is -0.56%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, OM is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for OM.Check BSGM's competition here
OM vs QTI Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, QTI has a market cap of 190.5M. Regarding current trading prices, OM is priced at $3.70, while QTI trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas QTI's P/E ratio is -3.49. In terms of profitability, OM's ROE is -0.56%, compared to QTI's ROE of +3.64%. Regarding short-term risk, OM is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check QTI's competition here
OM vs CVRX Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, CVRX has a market cap of 179.7M. Regarding current trading prices, OM is priced at $3.70, while CVRX trades at $6.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas CVRX's P/E ratio is -3.35. In terms of profitability, OM's ROE is -0.56%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, OM is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check CVRX's competition here
OM vs MDGS Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, OM is priced at $3.70, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas MDGS's P/E ratio is -0.27. In terms of profitability, OM's ROE is -0.56%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, OM is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for OM.Check MDGS's competition here
OM vs TLSI Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, TLSI has a market cap of 167.9M. Regarding current trading prices, OM is priced at $3.70, while TLSI trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas TLSI's P/E ratio is -2.41. In terms of profitability, OM's ROE is -0.56%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, OM is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check TLSI's competition here
OM vs QIPT Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, OM is priced at $3.70, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas QIPT's P/E ratio is -15.87. In terms of profitability, OM's ROE is -0.56%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, OM is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check QIPT's competition here
OM vs EDAP Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, EDAP has a market cap of 155.2M. Regarding current trading prices, OM is priced at $3.70, while EDAP trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas EDAP's P/E ratio is -5.31. In terms of profitability, OM's ROE is -0.56%, compared to EDAP's ROE of -0.65%. Regarding short-term risk, OM is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check EDAP's competition here
OM vs APYX Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, APYX has a market cap of 153.5M. Regarding current trading prices, OM is priced at $3.70, while APYX trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas APYX's P/E ratio is -16.68. In terms of profitability, OM's ROE is -0.56%, compared to APYX's ROE of -0.91%. Regarding short-term risk, OM is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check APYX's competition here
OM vs HYPR Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, HYPR has a market cap of 138.1M. Regarding current trading prices, OM is priced at $3.70, while HYPR trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas HYPR's P/E ratio is -3.93. In terms of profitability, OM's ROE is -0.56%, compared to HYPR's ROE of -0.97%. Regarding short-term risk, OM is more volatile compared to HYPR. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check HYPR's competition here
OM vs SNWV Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, SNWV has a market cap of 133.8M. Regarding current trading prices, OM is priced at $3.70, while SNWV trades at $15.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas SNWV's P/E ratio is 37.98. In terms of profitability, OM's ROE is -0.56%, compared to SNWV's ROE of -1.42%. Regarding short-term risk, OM is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check SNWV's competition here
OM vs QTRX Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, QTRX has a market cap of 132.6M. Regarding current trading prices, OM is priced at $3.70, while QTRX trades at $2.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas QTRX's P/E ratio is -1.20. In terms of profitability, OM's ROE is -0.56%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, OM is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check QTRX's competition here
OM vs TMCI Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, TMCI has a market cap of 130.2M. Regarding current trading prices, OM is priced at $3.70, while TMCI trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas TMCI's P/E ratio is -2.16. In terms of profitability, OM's ROE is -0.56%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, OM is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for OM.Check TMCI's competition here
OM vs NNOX Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, NNOX has a market cap of 120.4M. Regarding current trading prices, OM is priced at $3.70, while NNOX trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas NNOX's P/E ratio is -1.49. In terms of profitability, OM's ROE is -0.56%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, OM is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check NNOX's competition here
OM vs RPID Comparison May 2026
OM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OM stands at 68.5M. In comparison, RPID has a market cap of 120.4M. Regarding current trading prices, OM is priced at $3.70, while RPID trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OM currently has a P/E ratio of -0.69, whereas RPID's P/E ratio is -2.63. In terms of profitability, OM's ROE is -0.56%, compared to RPID's ROE of -0.95%. Regarding short-term risk, OM is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for OM.Check RPID's competition here